For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 2,338,345 | 2,453,826.75* | 2,386,244 | 2,753,963 |
| General and administrative | 2,507,383 | 2,161,960.5* | 1,976,335 | 1,969,828 |
| Total operating expenses | 4,845,728 | 4,615,787.25 | 4,362,579 | 4,723,791 |
| Loss from operations | -4,845,728 | -4,615,787.25* | -4,362,579 | -4,723,791 |
| Other income (expenses) | - | 60.5* | - | - |
| Other income | 173 | - | 248 | - |
| Stock-based inducement expense | - | 215,887.5* | - | - |
| Other expenses | - | - | - | 0 |
| Write off of deferred offering costs | - | 151,354.75* | 500,000 | - |
| Interest income (expense), net | - | - | 5,936 | 13,776 |
| Derivative expense | 896,722 | - | - | - |
| Interest income (expense), net | - | 2,903.5* | - | - |
| Change in fair value of earnout and derivative liabilities | - | - | - | 0 |
| Change in fair value of earnout liability | -19,500 | - | - | - |
| Total other income (expenses), net | - | -364,278.25* | - | - |
| Stock-based inducement expense | - | - | - | 707,300 |
| Interest income | 3,149 | - | - | - |
| Net loss | - | -4,980,065.5* | - | - |
| Gain from settlement of liabilities with vendors | - | - | - | 0 |
| Interest expense | 166,286 | - | - | - |
| Deemed dividend on series a, b and c preferred stock | - | 7,122,311.25* | - | - |
| Total other expenses, net | -1,040,186 | - | -493,816 | -693,524 |
| Deemed dividend on series d preferred stock | - | 19,113,468.25* | - | - |
| Net loss | -5,885,914 | - | -4,856,395 | -5,417,315 |
| Deemed dividend on series e preferred stock | - | 1,790,827* | - | - |
| Deemed dividend on series a, b and c preferred stock | - | - | - | 24,700,374 |
| Deemed dividend related to series c common warrants | - | 84,083* | - | 0 |
| Deemed dividend on series d preferred stock | - | - | 6,649,828 | - |
| Net loss attributable to common shareholders | -5,885,914 | -33,090,755 | -11,506,223 | -30,117,689 |
| Basic EPS | -0.2 | -7.823 | -9.1 | -61.71 |
| Diluted EPS | -0.2 | -7.823 | -9.1 | -61.71 |
| Basic Average Shares | 28,755,073 | 4,229,849* | 1,264,884 | 488,076 |
| Diluted Average Shares | 28,755,073 | 4,229,849* | 1,264,884 | 488,076 |
CERO THERAPEUTICS HOLDINGS, INC. (CEROW)
CERO THERAPEUTICS HOLDINGS, INC. (CEROW)